Press releases and news
2025
Camurus’ Interim Report Third Quarter 2025
Camurus receives highest level in My Green Lab certification
Camurus launches long-acting Oczyesa® for the treatment of acromegaly
Change in number of shares and votes in Camurus
Camurus submits its first CDP disclosure
Exercise in Camurus’ employee stock options program 2022/2026
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Camurus achieves ESG risk rating ‘low’ by Sustainalytics
Camurus CEO sells shares
Camurus’ Interim Report Second Quarter 2025
Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Change in number of shares and votes in Camurus
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Exercise in Camurus’ employee stock options program 2022/2026
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2025/2028
Resolutions at the annual general meeting 2025 in Camurus
Camurus to present at Jefferies Global Healthcare Conference
Camurus’ Interim Report January-March 2025
Camurus appoints Anders Vadsholt as Chief Financial Officer
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.